← back to search

Mauro Galeazzi

New York University · US
🔎 Find collaborators in Rheumatology · Molecular Biology →
Search 5.9M scientists by topic, h-index, country & funding — free.
Area of research
Rheumatology · Molecular Biology
Research interest
Research focused on Anakinra and Infliximab, with related work in Adalimumab, Rheumatoid arthritis, Etanercept. Notable publications include 'Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis', 'Obesity and reduction of the response rate to anti–tumor necrosis factor α in rheumatoid arthritis: An approach to a personalized medicine', and 'Anakinra treatment in drug-resistant Behcet’s disease: a case series'.
h-index
citations
2,501
works
33
NIH funding
primary concept
email

Recent publications

An observational prospective study on predictors of clinical response at six months in patients with active psoriatic arthritis treated with golimumab.
PubMed 2020cited by 19position: middle
Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis
Ophthalmology 2018cited by 257position: middledoi
Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study
Clinical Rheumatology 2018cited by 82position: middledoi
Response to Interleukin-1 Inhibitors in 140 Italian Patients with Adult-Onset Still’s Disease: A Multicentre Retrospective Observational Study
Frontiers in Pharmacology 2017cited by 105position: middledoi
Hydrostatic Pressure Regulates MicroRNA Expression Levels in Osteoarthritic Chondrocyte Cultures via the Wnt/β-Catenin Pathway
International Journal of Molecular Sciences 2017cited by 74position: middledoi
Comparison of efficacy of first- versus second-line adalimumab in patients with rheumatoid arthritis: experience of the Italian biologics registries.
PubMed 2017cited by 8position: middle
Adult-onset Still’s disease: an Italian multicentre retrospective observational study of manifestations and treatments in 245 patients
Clinical Rheumatology 2016cited by 105position: middledoi
A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwide Multi-Center Retrospective Observational Study
Frontiers in Pharmacology 2016cited by 88position: middledoi
Patient-reported impact of spondyloarthritis on work disability and working life: the ATLANTIS survey
Arthritis Research & Therapy 2016cited by 65position: middledoi
Arrhythmogenicity of Anti-Ro/SSA Antibodies in Patients With Torsades de Pointes
Circulation Arrhythmia and Electrophysiology 2016cited by 64position: middledoi
Drug survival of adalimumab in patients with rheumatoid arthritis over 10 years in the real-world settings: high rate remission together with normal function ability
Clinical Rheumatology 2016cited by 22position: middledoi
Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry.
PubMed 2015cited by 109position: middle
Current evidence in the field of the management with TNF-α inhibitors in psoriatic arthritis and concomitant hepatitis C virus infection
Expert Opinion on Biological Therapy 2015cited by 46position: middledoi
PFAPA syndrome and Behçet’s disease: a comparison of two medical entities based on the clinical interviews performed by three different specialists
Clinical Rheumatology 2015cited by 40position: middledoi
Diagnosis and classification of relapsing polychondritis
Journal of Autoimmunity 2014cited by 99position: middledoi
Caveats and truths in genetic, clinical, autoimmune and autoinflammatory issues in Blau syndrome and early onset sarcoidosis
Autoimmunity Reviews 2014cited by 89position: middledoi
Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet's disease
Autoimmunity Reviews 2014cited by 89position: middledoi
Inhibition of Interleukin-1 by Canakinumab as a Successful Mono-Drug Strategy for the Treatment of Refractory Behçet's Disease: A Case Series
Dermatology 2014cited by 80position: middledoi
Biological Treatments in Behçet’s Disease: Beyond Anti-TNF Therapy
Mediators of Inflammation 2014cited by 76position: middledoi
Key facts and hot spots on tumor necrosis factor receptor‐associated periodic syndrome
Clinical Rheumatology 2014cited by 62position: middledoi
Drug Retention Rates and Treatment Discontinuation among Anti-TNF-<i>α</i>Agents in Psoriatic Arthritis and Ankylosing Spondylitis in Clinical Practice
Mediators of Inflammation 2014cited by 56position: lastdoi
The labyrinth of autoinflammatory disorders: a snapshot on the activity of a third-level center in Italy
Clinical Rheumatology 2014cited by 36position: middledoi
Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: Results from the GISEA register
Joint Bone Spine 2014cited by 26position: middledoi
Anakinra treatment in drug-resistant Behcet’s disease: a case series
Clinical Rheumatology 2013cited by 131position: middledoi
The expanding spectrum of low-penetrance TNFRSF1A gene variants in adults presenting with recurrent inflammatory attacks: Clinical manifestations and long-term follow-up
Seminars in Arthritis and Rheumatism 2013cited by 82position: middledoi
Monogenic Autoinflammatory Syndromes: State of the Art on Genetic, Clinical, and Therapeutic Issues
International Journal of Rheumatology 2013cited by 80position: middledoi
Biological Treatments: New Weapons in the Management of Monogenic Autoinflammatory Disorders
Mediators of Inflammation 2013cited by 75position: middledoi
Long-term safety of anti-TNF-α in PsA patients with concomitant HCV infection: a retrospective observational multicenter study on 15 patients
Clinical Rheumatology 2013cited by 67position: middledoi
First Report of Circulating MicroRNAs in Tumour Necrosis Factor Receptor-Associated Periodic Syndrome (TRAPS)
PLoS ONE 2013cited by 48position: middledoi
High rate of disease remission in moderate rheumatoid arthritis on etanercept therapy: data from GISEA, the Italian biologics register
Clinical Rheumatology 2013cited by 10position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Luca Cantarini · Misericordia University18 papers (2013–2017)Francesco Caso · University of Padua15 papers (2013–2015) · 12 papers (2013–2015) · 11 papers (2013–2014)Luisa Costa · University of Padua11 papers (2013–2015) · 10 papers (2013–2015)Leonardo Punzi · University of Padua10 papers (2013–2016)Florenzo Iannone · University of Padua8 papers (2012–2020) · 7 papers (2013–2014)Giovanni Lapadula · University of Ferrara7 papers (2012–2017)Rolando Cimaz · KU Leuven7 papers (2013–2014)Roberta Ramonda · University of Padua6 papers (2013–2020)Elisa Gremese · University of Glasgow5 papers (2012–2017) · 5 papers (2012–2020)Fabiola Atzeni · University of Aberdeen4 papers (2012–2017)Giuseppe Lopalco · University of Padua4 papers (2014–2015)Flora Magnotti · Université Claude Bernard Lyon 14 papers (2013–2014) · 4 papers (2012–2017)Gianfranco Ferraccioli · Centro Studi GISED4 papers (2012–2017)Piercarlo Sarzi‐Puttini · University of Ferrara4 papers (2013–2017)
Looking for a research collaborator?
Search millions of scientists by field, institution, impact, and funding status — see their work, find their email, and reach out directly.
Find collaborators in Rheumatology · Molecular Biology →